deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03367546

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Haploidentical Donor T-cell Replete Allogeneic Hematopoietic Cell Transplant Following Reducing Intensity Conditioning for Patients With Selected High Risk Non-Malignant Disease

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions Cerebral Adrenoleukodystrophy High Risk Hematologic Disorders Inherited Metabolic Disorders Sickle Cell Disease Thalassemia
Interventions Blood and Marrow Transplant
Updated 13 times since 2017 Last updated: Jul 9, 2024 Started: Jul 2, 2018 Primary completion: Dec 19, 2022 Completion: Dec 19, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study no longer needed

Other terminated trials from Masonic Cancer Center, University of Minnesota

See all terminations from Masonic Cancer Center, University of Minnesota

A PHASE2 clinical study on Cerebral Adrenoleukodystrophy and High Risk Hematologic Disorders, this trial is terminated or withdrawn. The trial is conducted by Masonic Cancer Center, University of Minnesota and has accumulated 13 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Apr 2020 · 12 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jun 2022 · 12 months · monthly snapshot~Jun 2022 – ~Jul 2023 · 13 months · monthly snapshot~Jul 2023 – ~Mar 2024 · 8 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Aug 2024 [monthly]

    Terminated PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  5. Jul 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 8 earlier versions

  1. Jun 2022 — Jul 2023 [monthly]

    Recruiting PHASE2

  2. Jun 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  4. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Apr 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  6. Oct 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jun 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE2

  8. Dec 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Masonic Cancer Center, University of Minnesota
Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations